Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

608 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.
Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA. Goldstein JB, et al. Among authors: subbiah v. Oncotarget. 2017 Aug 3;8(50):87163-87173. doi: 10.18632/oncotarget.19897. eCollection 2017 Oct 20. Oncotarget. 2017. PMID: 29152071 Free PMC article.
Gastric adenocarcinoma in children and adolescents.
Subbiah V, Varadhachary G, Herzog CE, Huh WW. Subbiah V, et al. Pediatr Blood Cancer. 2011 Sep;57(3):524-7. doi: 10.1002/pbc.23051. Epub 2011 Jan 24. Pediatr Blood Cancer. 2011. PMID: 21744476 Free PMC article.
A tale of two histiocytic disorders.
Janku F, Munoz J, Subbiah V, Kurzrock R. Janku F, et al. Among authors: subbiah v. Oncologist. 2013;18(1):2-4. doi: 10.1634/theoncologist.2012-0440. Epub 2013 Jan 8. Oncologist. 2013. PMID: 23299771 Free PMC article.
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.
Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Subbiah IM, et al. Among authors: subbiah v. Oncotarget. 2013 Jan;4(1):156-65. doi: 10.18632/oncotarget.832. Oncotarget. 2013. PMID: 23391555 Free PMC article. Clinical Trial.
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.
Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. Jardim DL, et al. Among authors: subbiah v. PLoS One. 2014 Feb 19;9(2):e89388. doi: 10.1371/journal.pone.0089388. eCollection 2014. PLoS One. 2014. PMID: 24586741 Free PMC article.
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. Jardim DL, et al. Among authors: subbiah v. Oncotarget. 2014 Apr 15;5(7):1837-45. doi: 10.18632/oncotarget.1828. Oncotarget. 2014. PMID: 24742823 Free PMC article. Clinical Trial.
608 results